TERA PROBE INC by TERA PROBE INC. Stock (OTC: TPRBF)

Latest news for TERA PROBE INC by TERA PROBE INC. (OTC:TPRBF) Stock

TERA PROBE INC by TERA PROBE INC.

<p>ScanTech AI Systems Inc. (NASDAQ:&nbsp; STAI, or ScanTech AI) , a security solution provider offering one of the world's most advanced non-intrusive "fixed-gantry" CT screening technologies, &nbsp;announced today, following its successful merger with ScanTech Identification Beam Systems, LLC, &nbsp;that it now seeks to become a leading security solution provider for U.S. and global airport, cargo, homeland, and border security screening.</p>


STAI

ScanTech AI Systems Charts Growth Path Following Successful De-SPAC Transaction; Shares Spike Higher

Earnings

News

Jefferies Quarterly Investment Banking Net Revenues $987M, Up 73% YoY

Guidance

Greenbrier Sees FY25 Revenue $3.35B-$3.65B Vs $3.544B Est.

<p>The earnings results for <strong>Penguin Solutions</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENG#NASDAQ">PENG</a>) for Q1 were made public on Wednesday, January 8, 2025 at 04:05 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Penguin Solutions beat estimated earnings by 26.0%, reporting an EPS of $0.49 versus an estimate of $0.39.</p>
<p>Revenue was up $66.86 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>In the previous quarter, the company missed on EPS by $0.03, resulting in a 23.0% drop change in the share price the following day.</p>
<p>Here's a look at Penguin Solutions's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.40</td>
<td>0.30</td>
<td>0.25</td>
<td>0.16</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.37</td>
<td>0.37</td>
<td>0.27</td>
<td>0.24</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>325.00M</td>
<td>300.00M</td>
<td>283.79M</td>
<td>275.00M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>311.15M</td>
<td>300.58M</td>
<td>284.82M</td>
<td>274.25M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Penguin Solutions management provided guidance for FY 2025, expecting earnings between $1.3 and $1.7 per share.</p>
<p>To track all earnings releases for Penguin Solutions <a href="https://www.benzinga.com/quote/PENG/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Penguin Solutions, Inc. - Ordinary Shares

PENG

Earnings Breakdown: Penguin Solutions Q1

<p><strong>Pricesmart</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSMT#NASDAQ">PSMT</a>) released its Q1 earnings on Wednesday, January 8, 2025 at 04:01 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Pricesmart missed estimated earnings by -8.0%, reporting an EPS of $1.21 versus an estimate of $1.31.</p>
<p>Revenue was up $91.94 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>The company missed on EPS by $0.09 in the previous quarter, leading to a 7.000000000000001% drop share price change the next day.</p>
<p>Here's a look at Pricesmart's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.03</td>
<td>1.01</td>
<td>1.24</td>
<td>1.09</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.94</td>
<td>1.08</td>
<td>1.31</td>
<td>1.24</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.22B</td>
<td>1.21B</td>
<td>1.28B</td>
<td>1.16B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.23B</td>
<td>1.23B</td>
<td>1.29B</td>
<td>1.17B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Pricesmart <a href="https://www.benzinga.com/quote/PSMT/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PSMT

Earnings Summary: Pricesmart Q1

CNBC: Disney Announces 157M Ad-Supported Monthly Active Users Across Streaming Services

<p>Citigroup  analyst John Yu   maintains Coupang (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPNG#NYSE">CPNG</a>) with a Buy and lowers the price target from $31 to $28.</p>


Price Target

Analyst Ratings

CPNG

Citigroup Maintains Buy on Coupang, Lowers Price Target to $28

<p>Greenbrier Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBX#NYSE">GBX</a>) reported quarterly earnings of $1.72 per share which beat the analyst consensus estimate of $1.16 by 48.28 percent.  The company reported quarterly sales of $876.00 million which beat the analyst consensus estimate of $849.50 million by 3.12 percent.  This is a 8.31 percent increase over sales of $808.80 million the same period last year.</p>


Earnings Beats

Greenbrier Companies Q1 2025 GAAP EPS $1.72 Beats $1.16 Estimate, Sales $876.00M Beat $849.50M Estimate

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

Avadel Pharmaceuticals Sees FY25 Net Product Revenue $240M-$260M Vs $291.526M Est.

<p>Net sales for the first eighteen weeks were $94.04 billion, an increase of 8.0 percent from $87.07 billion last year.</p>


COST

Costco Wholesale December Comparable Sales Up 7.4%; Comp Sales, Excluding Impacts From Changes In Gasoline Prices And Foreign Exchange, Up 9.9%

Avadel Pharmaceuticals Sees Prelim. Q4 Revenue ~$50.0M Vs $52.312M Est.

<p>Citigroup  analyst Ronald Josey   upgrades Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) from Neutral to Buy and raises the price target from $195 to $277.</p>


Upgrades

CVNA

Citigroup Upgrades Carvana to Buy, Raises Price Target to $277

Dividends

Jefferies Increases Quarterly Dividend By 14.3% To $0.40/Share

Costco Wholesale Reports Net Sales Of $27.52B For Retail Month Of December, Up 9.9% From $25.03B Last Year

<p>Jefferies Financial Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JEF#NYSE">JEF</a>) reported quarterly earnings of $0.93 per share which beat the analyst consensus estimate of $0.91 by 2.2 percent.  The company reported quarterly sales of $1.957 billion which beat the analyst consensus estimate of $1.775 billion by 10.26 percent.  This is a 63.46 percent increase over sales of $1.197 billion the same period last year.</p>


Jefferies Financial Gr Q4 2024 GAAP EPS $0.93 Beats $0.91 Estimate, Sales $1.957B Beat $1.775B Estimate

<p>The earnings results for <strong>Franklin Covey</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) for Q1 were made public on Wednesday, January 8, 2025 at 04:04 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Franklin Covey missed estimated earnings by -59.0%, reporting an EPS of $0.09 versus an estimate of $0.22.</p>
<p>Revenue was up $687 thousand from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company beat on EPS by $0.07 which was followed by a 15.0% drop in the share price the next day.</p>
<p>Here's a look at Franklin Covey's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.82</td>
<td>0.39</td>
<td>0.05</td>
<td>0.23</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.89</td>
<td>0.43</td>
<td>0.06</td>
<td>0.36</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>80.38M</td>
<td>72.12M</td>
<td>62.02M</td>
<td>65.88M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>84.12M</td>
<td>73.37M</td>
<td>61.34M</td>
<td>68.40M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Franklin Covey <a href="https://www.benzinga.com/quote/FC/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Breakdown: Franklin Covey Q1

<p>Tyler Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) has outperformed the market over the past 20 years by 15.63% on an annualized basis producing an average annual return of 23.93%. Currently, Tyler Technologies has a market capitalization of $24.62 billion. </p>
<p><strong>Buying $100 In TYL:</strong> If an investor had bought $100 of TYL stock 20 years ago, it would be worth <strong>$7,422.19</strong> today based on a price of $575.22 for TYL at the time of writing.</p>
<h3>Tyler Technologies's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736370911_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

Here's How Much You Would Have Made Owning Tyler Technologies Stock In The Last 20 Years

<p><strong>Saratoga Investment</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAR#NYSE">SAR</a>) reported its Q3 earnings results on Wednesday, January 8, 2025 at 04:05 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Saratoga Investment beat estimated earnings by 7.000000000000001%, reporting an EPS of $0.9 versus an estimate of $0.84.</p>
<p>Revenue was down $461 thousand from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>In the previous quarter, the company beat on EPS by $0.39, resulting in a 5.0% increase change in the share price the following day.</p>
<p>Here's a look at Saratoga Investment's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.94</td>
<td>0.93</td>
<td>0.95</td>
<td>1.03</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.33</td>
<td>1.05</td>
<td>0.94</td>
<td>1.01</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>37.12M</td>
<td>36.47M</td>
<td>36.43M</td>
<td>36.08M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>43.00M</td>
<td>38.68M</td>
<td>37.23M</td>
<td>36.34M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Saratoga Investment <a href="https://www.benzinga.com/quote/SAR/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Breakdown: Saratoga Investment Q3

<p><strong>2025 Milestones</strong></p>
<ul>
<li>On track to report data in the first quarter of 2025 from the Phase 1 clinical trial of VG-3927, including single-ascending and multiple-ascending dose data from healthy volunteers, data from a single cohort of AD patients and data from an elderly patient cohort. Vigil expects to use these data to inform the development strategy for subsequent and larger trials evaluating VG-3927 in AD.</li>
<li>Final analysis from the IGNITE Phase 2 clinical trial, including all patients at 12 months dosed with either 20 mg/kg or 40 mg/kg of iluzanebart, is planned for the second quarter of 2025. The Company will pursue an accelerated approval pathway for iluzanebart in ALSP and expects to share an update on its progress when the final analysis is reported.</li>
</ul>
<p>"Building on the momentum from 2024, we plan to report key data for both VG-3927 and iluzanebart in the first half of 2025. We expect these development milestones will further support our efforts to bring potentially transformative therapies to patients with ALSP and AD," concluded Dr. Magovčević-Liebisch. "Looking ahead, we aim to leverage our deep expertise in microglial biology to explore additional targets to treat other rare and common neurodegenerative diseases."</p>


Biotech

General

VIGL

Vigil Neuroscience Plans To Report Data From Phase 1 VG-3927 Trial For AD In Q1 2025; Final Analysis Of IGNITE Phase 2 Iluzanebart Trial For ALSP In Q2 2025; Pursues Accelerated Approval; Strategy Involves Exploring New Neurodegenerative Disease Targets

<p>Redburn Atlantic  analyst Russell Quelch   initiates coverage on RELX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RELX#NYSE">RELX</a>) with a Buy rating.</p>


Comments

TERA PROBE INC by TERA PROBE INC.

News

Latest news for TERA PROBE INC by TERA PROBE INC. (OTC:TPRBF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga